लोड हो रहा है...

Advertisement

INOVIO Reports Positive Interim Phase 1/2 Trial Results For INO-3107 For Respiratory Papillomatosis

RTTNews | 1029 दिनों पहले

INOVIO Reports Positive Interim Phase 1/2 Trial Results For INO-3107 For Respiratory Papillomatosis

(RTTNews) - Biotechnology company Inovio Pharmaceuticals Inc. (INO) announced Thursday positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.

In the first cohort of 21 participants, INO-3107 showed a statistically significant improvement in the clinical endpoint of the number of surgical interventions needed to control papilloma growth.

INO-3107 was also observed to be well-tolerated and immunogenic in the trial. INO-3107 received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in July 2020.

INO-3107 was evaluated in a Phase 1/2 open-label, multicenter trial to assess its safety, tolerability, immunogenicity, and efficacy in 32 participants with HPV 6 and/or HPV 11-associated RRP.

Results from the second cohort of 11 patients are expected in the first half of 2023.

For More Such Health News, visit rttnews.com

टैग: INO

read more

Inovio Pharma Receives FDA Feedback On Submission Of BLA For INO-3107 To Treat RRP

Inovio Pharma Receives FDA Feedback On Submission Of BLA For INO-3107 To Treat RRP

Biotechnology company Inovio Pharmaceuticals, Inc. (INO) announced Tuesday that it has received feedback from the U.S. Food and Drug Administration (FDA) that data from its completed Phase 1/2 trial of INO-3107 for the treatment of RRP could support INOVIO's submission of a BLA for review under the FDA's accelerated approval program.

RTTNews | 667 दिनों पहले

INOVIO Says FDA Grants Breakthrough Therapy Designation For INO-3107; Stock Up 15%

INOVIO Says FDA Grants Breakthrough Therapy Designation For INO-3107; Stock Up 15%

Biotechnology company Inovio Pharmaceuticals, Inc. (INO) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis (RRP).

RTTNews | 700 दिनों पहले

INOVIO Pharma Announces Positive Results From Phase 1b Clinical Trial Evaluating INO-4201

INOVIO Pharma Announces Positive Results From Phase 1b Clinical Trial Evaluating INO-4201

Biotechnology company INOVIO Pharmaceuticals, Inc. (INO) announced Thursday positive results from a Phase 1b clinical trial evaluating INO-4201, a DNA vaccine candidate, as a booster in healthy adult participants who previously received a single injection of Ervebo.

RTTNews | 917 दिनों पहले

INOVIO Announces Corporate Reorganization, Including Workforce Reduction, To Reduce Expenses

INOVIO Announces Corporate Reorganization, Including Workforce Reduction, To Reduce Expenses

Biotechnology company INOVIO (INO) announced Tuesday that it has implemented a corporate reorganization designed to extend its cash runway and to focus on key clinical programs with the goal to drive long-term growth.

RTTNews | 1115 दिनों पहले

Win Streak May End For Japan Stock Market

Win Streak May End For Japan Stock Market

The Japan stock market has moved higher in three consecutive sessions, advancing more than 760 points or 1.9 percent along the way. The Nikkei 225 now sits just shy of the 41,060-point plateau although it may spin its wheels on Friday.

RTTNews | 7 मिनटों पहले

South Korea Shares May Run Out Of Steam On Friday

South Korea Shares May Run Out Of Steam On Friday

The South Korea stock market has moved higher in four straight sessions, advancing almost 110 points or 3.6 percent along the way. The KOSPI now sits just above the 3,225-point plateau although the rally may stall on Friday.

RTTNews | 22 मिनटों पहले

Japan Data On Tap For Friday

Japan Data On Tap For Friday

Japan will release a batch of data on Friday, headlining a modest day for Asia-Pacific economic activity. On tap are June figures for household spending and current account and July numbers for bank lending and the eco watchers survey.

RTTNews | 1घंटे 22 मिनट पहले

U.S. Dollar Rises As Waller Emerges As Potential Fed Chair Successor

U.S. Dollar Rises As Waller Emerges As Potential Fed Chair Successor

The U.S. dollar climbed against its most major counterparts in the New York session on Thursday, as Federal Reserve governor Christopher Waller emerged as a top candidate to replace Chair Jerome Powell.

RTTNews | 2घंटे 9 मिनट पहले

शर्तें | गोलनीयता | साइट का मैप | Site Map Calendar

&प्रतिलिपि; 2025 Myfxbook Ltd. सर्वाधिकार सुरक्षित.

उच्च जोखिम चेतावनी: फॉरन एक्सचेंज ट्रेडिंग में उच्च स्तर का खतरा होता है जो हर निवेशकों के लिए सही नहीं हो सकता. लीवरेज अधिकतम खातर और हानि के अनावरण को उत्पन्न करता है. इससे पहले कि आप निर्णय लें फॉरन एक्सचेंज में ट्रेड करने का, ध्यान अपने निवेश के उद्देश्यों, अनुभव स्तर, और खतरा उठाने की सहिष्णुता पर विचार करें. आप कुछ या अपनी प्रारंभिक निवेश को खो सकते हैं. बिल्कुल भी उस पैसे को निवेश ना करें जो आप खोने को बर्दाश्त नहीं कर सकते. अपने आप को शिक्षित करें उन खतरों से जो फॉरन एक्सचेंज ट्रेडिंग से संबंधित हैं, और सलाह लें किसी स्वतंत्र आर्थिक या कर सलाहकार से अगर आपके पास कोई भी प्रश्न हैं तो. कोई भी डाटा या जानकारों जो दी जाती है वे केवल सूचनात्मक उद्देश्यों के लिए है, और यब ट्रेडिंग आशय या सलाह पर नियत नहीं है. पिछले निष्पादन भविष्य के परिणामों के लिए परियाचक नहीं हैं.